FDA Category 2 is a recurring topic in our peptide coverage. This hub collects every article tagged FDA Category 2, newest first, each evidence-graded and tied to real, verifiable sources.
The anchor safety guide to the peptide class — separating what the molecule does from what is actually in the vial, with the load-bearing contraindications, interactions, injection risks, and the shifting 2026 FDA/WADA landscape.
What peptides actually are, how they differ from drugs, hormones and supplements, the major functional classes, and — crucially — what the human evidence does and doesn't support, from Grade-A medicines to Grade C-D research peptides.
A single, evidence-graded map of what the published literature actually shows for the peptide field — separating the handful of Grade-A, FDA-approved peptides from the much larger group whose claims rest on animal data, mechanism, or marketing alone.
"Legal" is not one question but five — FDA approval, compounding eligibility, DEA scheduling, WADA sport status, and state telehealth law. A date-stamped 2026 explainer of where peptides actually stand.
An evidence-graded look at the three peptides marketed for PTSD and trauma — oxytocin, Selank and Semax — separating the mixed human oxytocin RCTs from anxiety-only and preclinical claims.
An evidence-graded review of the peptides marketed for whiplash and neck soft-tissue injury. The honest 2026 verdict: there is no human evidence — no RCT, cohort, or registered trial — for any peptide in the cervical spine; the strongest case tops out at rat ligament and tendon models.
An evidence-first ranking of the GH secretagogues sold for 'growth hormone optimization' — tesamorelin, MK-677, CJC-1295, sermorelin and ipamorelin — separating what raises GH/IGF-1 in humans from what only sounds like it should.
An evidence-graded review of the peptides marketed for endurance and aerobic performance — elamipretide (SS-31), MOTS-c and AOD-9604. The honest 2026 verdict: no peptide is proven to raise VO₂max or race performance in healthy humans, the category is preclinical-dominant, and MOTS-c is WADA-banned at all times.
A clinical, evidence-first look at the peptides pitched for lateral and medial epicondylitis — BPC-157 and TB-500/thymosin β-4 — and why both are graded C (preclinical only) for the elbow.
A clinical, evidence-ranked look at the peptides marketed for back injury, spinal soft-tissue repair, and disc health — what the published data actually supports, and what is marketing.
An evidence-first ranking of the peptides most studied for aging and healthspan — elamipretide, GHK-Cu, thymalin, epitalon and MOTS-c — separating real human data from rodent and in-vitro hype.
A clinical monograph on Thymosin Beta-4 (Tβ4) — the actin-sequestering repair peptide with a real, decades-long human-trial record in ocular, dermal and cardiac repair. Grade B human evidence, no FDA-approved product, and an unsettled 2026 legal status.
A clinical monograph on Ac-SDKP (goralatide/seraspenide), the N-terminal tetrapeptide fragment of thymosin beta-4. Human chemoprotection data (Grade B), preclinical-only anti-fibrosis, and a WADA-prohibited 2026 status.
A clinical monograph on thymosin alpha-1 (Zadaxin/thymalfasin) — an immune-calibrating thymic peptide with real human RCTs in hepatitis B, a negative phase 3 sepsis trial, and an unsettled 2026 US legal status.
A clinical monograph on TB-500 — the synthetic thymosin β4 fragment (Ac-LKKTETQ) marketed for tendon, muscle and tissue repair. Strong preclinical biology, no human efficacy RCT of the fragment, and an unsettled 2026 legal status.
A clinical monograph on Pentadeca Arginate (PDA) — the L-arginine salt of BPC-157 marketed for tendon, gut and wound healing. Zero PDA-specific studies, borrowed preclinical data, and an unsettled 2026 legal status.
A clinical monograph on Pentadeca Arginate — the L-arginine salt of BPC-157. No studies exist under the 'PDA' name; the borrowed parent evidence is 35:1 preclinical, with zero human RCTs and an unsettled 2026 legal status.
A clinical monograph on PEG-MGF — the pegylated Mechano Growth Factor E-peptide marketed for muscle repair and recovery. Preclinical-only evidence, no human trials, and a restricted 2026 legal status.
A clinical monograph on N-Acetyl Semax Amidate — the terminally-stabilized analog of the Russian nootropic Semax. No human or animal data on the modified molecule, an unproven potency story, and an unsettled 2026 legal status.
A clinical monograph on N-Acetyl Selank Amidate — a twice-stabilized analog of the Russian anxiolytic peptide Selank. No dedicated human or animal study exists; every claim is extrapolated, placing the analog itself at evidence grade D.
FDA Category 2 is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged FDA Category 2, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.